TWIST BIOSCIENCE CORP (TWST) Stock Price, Forecast & Analysis
NASDAQ:TWST • US90184D1000
TWST Key Statistics, Chart & Performance
The current stock price of TWST is 48.59 USD. In the past month the price increased by 7.62%. In the past year, price increased by 17.62%.
TWST Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to TWST. When comparing the yearly performance of all stocks, TWST is one of the better performing stocks in the market, outperforming 90.06% of all stocks.
TWST Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to TWST. TWST has a great financial health rating, but its profitability evaluates not so good.
TWST Financial Highlights
Over the last trailing twelve months TWST reported a non-GAAP Earnings per Share(EPS) of -2.08. The EPS increased by 38.46% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -12% | ||
| ROE | -16.79% | ||
| Debt/Equity | 0 |
TWST Forecast & Estimates
17 analysts have analysed TWST and the average price target is 48.35 USD. This implies a price decrease of -0.5% is expected in the next year compared to the current price of 48.59.
For the next year, analysts expect an EPS growth of 18.93% and a revenue growth 15.9% for TWST
TWST Ownership
TWST Latest News, Press Relases and Analysis
TWST Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.48 | 397.325B | ||
| AMGN | AMGEN INC | 16.63 | 201.795B | ||
| GILD | GILEAD SCIENCES INC | 16.97 | 187.839B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.39 | 120.999B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.78 | 82.427B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 50.19 | 44.414B | ||
| INSM | INSMED INC | N/A | 35.17B | ||
| NTRA | NATERA INC | N/A | 29.514B | ||
| BIIB | BIOGEN INC | 12.62 | 28.182B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.06 | 20.385B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About TWST
Company Profile
Twist Bioscience Corp. engages in the development of a proprietary semiconductor-based synthetic DNA manufacturing process. The company is headquartered in South San Francisco, California and currently employs 979 full-time employees. The company went IPO on 2018-10-31. The firm's platform's core is a proprietary technology that specializes in manufacturing synthetic DNA by writing DNA on a silicon chip. The company has applied its technology to manufacture a range of synthetic DNA-based products, including synthetic genes, tools for next generation sequencing (NGS) sample preparation, and antibody libraries for drug discovery and development, all designed to enable its customers to conduct research. Its gene products include multiplexed gene fragments, express genes, clonal genes and gene fragments. The firm also manufactures synthetic ribonucleic acid (RNA) as well as antibody proteins. The firm's synthetic DNA tools are used in fields, such as medicine, agriculture, industrial chemicals and defense. The company has minority ownership in Atlas Data Storage, Inc.
Company Info
TWIST BIOSCIENCE CORP
681 Gateway Blvd.
South San Francisco CALIFORNIA 94080 US
CEO: Emily M. Leproust
Employees: 923
Phone: 18007190671
TWIST BIOSCIENCE CORP / TWST FAQ
Can you describe the business of TWIST BIOSCIENCE CORP?
Twist Bioscience Corp. engages in the development of a proprietary semiconductor-based synthetic DNA manufacturing process. The company is headquartered in South San Francisco, California and currently employs 979 full-time employees. The company went IPO on 2018-10-31. The firm's platform's core is a proprietary technology that specializes in manufacturing synthetic DNA by writing DNA on a silicon chip. The company has applied its technology to manufacture a range of synthetic DNA-based products, including synthetic genes, tools for next generation sequencing (NGS) sample preparation, and antibody libraries for drug discovery and development, all designed to enable its customers to conduct research. Its gene products include multiplexed gene fragments, express genes, clonal genes and gene fragments. The firm also manufactures synthetic ribonucleic acid (RNA) as well as antibody proteins. The firm's synthetic DNA tools are used in fields, such as medicine, agriculture, industrial chemicals and defense. The company has minority ownership in Atlas Data Storage, Inc.
What is the current price of TWST stock?
The current stock price of TWST is 48.59 USD. The price decreased by -7.43% in the last trading session.
Does TWIST BIOSCIENCE CORP pay dividends?
TWST does not pay a dividend.
What is the ChartMill technical and fundamental rating of TWST stock?
TWST has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What sector and industry does TWIST BIOSCIENCE CORP belong to?
TWIST BIOSCIENCE CORP (TWST) operates in the Health Care sector and the Biotechnology industry.
Would investing in TWIST BIOSCIENCE CORP be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on TWST.
Can you provide the growth outlook for TWIST BIOSCIENCE CORP?
The Revenue of TWIST BIOSCIENCE CORP (TWST) is expected to grow by 15.9% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.